This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant Neoplasm of Ovary, C56난소의 악성신생물 (난소암)

Special Copayment Reduction V193 — copayment 5% of covered medical care costs applied for 5 years from the date of cancer patient registration (Cancer Control Act and National Health Insurance special copayment reduction regulations)
Adult onset: very high | ICD-10: C56
Contents (Table of Contents)
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Ovarian cancer is the gynecologic malignancy with the highest mortality, and the history of its clinical recognition developed relatively late. The first systematic description of ovarian neoplasms dates back to the early 1800s epoch. In 1809, Ephraim McDowell of Kentucky, USA, successfully performed surgery to remove an ovarian cyst, which is recorded as the beginning of intra-abdominal surgery. In 1809 this operation was performed without anesthesia, but the patient survived, proving for the first time the feasibility of abdominal surgery.

In the late 19th to early 20th centuries, ovarian malignancies began to be resected surgically, but treatment outcomes were extremely poor. In 1958, the first cooperative clinical trial group, the predecessor of the US GOG (Gynecologic Oncology Group), was formed, and systematic clinical research on gynecologic malignancies began. In 1976, the GOG evaluated the efficacy of alkylating agent-based chemotherapy (chlorambucil, cyclophosphamide) in treating ovarian cancer.

In the 1970s, when the anticancer effect of cisplatin was confirmed, a revolutionary change occurred in the treatment of ovarian cancer. In 1989, paclitaxel (Taxol) was reported to be highly effective in ovarian cancer, and in 1996 the GOG-111 and OV10 clinical trials established carboplatin + paclitaxel combination therapy as the standard first-line chemotherapy.

In 2003, as the association of BRCA1 (discovered 1994, Myriad Genetics) and BRCA2 (discovered 1995) with ovarian cancer risk was systematically analyzed, the concept of hereditary ovarian cancer was established. The lifetime risk of ovarian cancer in women with BRCA1/2 mutations is reported to be 40–60% and 15–30%, respectively.

In 2014–2015, olaparib (a PARP inhibitor) received FDA and EMA approval for BRCA1/2-mutant recurrent ovarian cancer, opening a new era of targeted therapy. Subsequently, the indications for niraparib (2017), rucaparib (2016), and olaparib/niraparib maintenance therapy were expanded, and combined maintenance therapy with bevacizumab + olaparib (PAOLA-1) was also established. In 2022, the era of precision oncology with treatment selection based on BRCA/HRD began in earnest in ovarian cancer. In March 2024, mirvetuximab soravtansine (Elahere) received full FDA approval for folate receptor α (FRα)-positive platinum-resistant ovarian cancer, opening a new chapter in ADC (antibody-drug conjugate) therapy.

2. Causes

The causes of ovarian cancer vary by histologic type. Epithelial ovarian carcinoma (EOC) accounts for about 90% of all ovarian cancers and is the most studied type.

Genetic causes

Reproductive and endocrine risk factors

Environmental factors

3. Genetics

The genomic features of ovarian cancer differ distinctly by histologic type, and TCGA's analysis of high-grade serous ovarian cancer (2011) provides the most comprehensive data.

Genomic features of high-grade serous ovarian cancer (HGSOC)

Low-grade serous ovarian cancer (LGSOC) and other histologic types

HRD testing and clinical significance

HRD (homologous recombination deficiency) status is a key biomarker for predicting sensitivity to PARP inhibitors and platinum chemotherapy. Commercial HRD tests such as the Myriad myChoice HRD test and FoundationOne are used clinically. In Korea, BRCA1/2 germline testing and tumor tissue HRD score testing are covered by National Health Insurance.

4. General epidemiology

Ovarian cancer is the gynecologic malignancy with the highest mortality; worldwide, about 313,000 women are diagnosed and about 207,000 die each year (2020). In Korea too, incidence is gradually increasing, and mortality has not declined.

Global situation

Incidence is high in developed countries (North America and Western Europe ASR about 10–12/100,000) and relatively low but increasing in East Asia. More than about 40% are diagnosed with distant metastasis (stage IV), so the 5-year survival rate is low.

Situation in Korea

In Korea, as of 2020, the age-standardized incidence of ovarian cancer is estimated at about 8–9 per 100,000 women. The 5-year relative survival rate is about 44.4–63.8%, the lowest among the major gynecologic cancers. Together with pancreatic cancer, it shows a trend of increasing mortality. The median age at diagnosis is about 55–60 years, and it is not uncommon in the 30s–40s. Clear cell carcinoma (CCC) shows a relatively higher proportion in East Asian women, such as in Korea and Japan, than in Western women (about 10–14%).

CategoryFigureNotes
New diagnoses worldwide (2020)About 313,0008th most common cancer in women
Korean 5-year survival rate44.4% (distant metastasis) / 63.8% (overall)Based on KCCR
Proportion of clear cell carcinoma in Korea~10~14%Higher than in Western countries (5–6%)
Proportion with BRCA1/2 mutations~15~20%Germline, HGSOC
Proportion at stage III–IV at diagnosis>40%Nonspecific symptoms, late detection
First-line PARP inhibitor maintenance PFS in Korea (2023)Median 45.3 monthsBRCA mut, olaparib/niraparib cohort of 96 patients

5. Pathophysiology

Pathophysiology of high-grade serous ovarian cancer (HGSOC)

Understanding of the origin of HGSOC has changed greatly over the past 10–15 years. Traditionally it was understood to originate from the ovarian surface epithelium (OSE) or ovarian cortical inclusion cysts, but the 'tubal origin hypothesis' now predominates: HGSOC arises from cells of the fallopian tube epithelium showing the p53 signature, particularly at the fimbriated end of the tube. A TP53 mutation occurs as an early event in the secretory cells of the fallopian tube, and as HRD due to loss of BRCA1/2 function is superimposed, genomic instability increases sharply, progressing from STIC (serous tubal intraepithelial carcinoma) → invasive HGSOC. The finding of STIC in the fimbriae of fallopian tubes removed during BRCA1/2 prophylactic surgery (risk-reducing salpingo-oophorectomy, RRSO) is strong evidence for the tubal origin hypothesis.

Pathophysiology of low-grade serous ovarian cancer (LGSOC)

A model of sequential progression from serous borderline tumor (SBT) → LGSOC is supported. MAPK pathway mutations such as KRAS, BRAF, NRAS and MAP2K1 are observed at an early stage, suggesting a pathogenesis completely different from HGSOC. LGSOC is resistant to chemotherapy but sensitive to MEK inhibitors.

Pathophysiology of clear cell carcinoma (CCC)

Endometriosis is strongly supported as a precursor lesion of CCC and endometrioid ovarian cancer. Oxidative stress due to excessive iron accumulation in endometriomas and ARID1A mutation (loss of BAF250a) impair the function of the SWI/SNF complex, causing failure of chromatin opening and gene expression regulation. Superimposed activation of the PI3K/AKT/mTOR pathway by PIK3CA mutation leads to progression to invasive CCC.

HRD and PARP inhibitor sensitivity

Cells with a damaged homologous recombination repair (HRR) pathway (HRD) cannot repair the single-strand DNA breaks induced by PARP inhibitors, so double-strand breaks accumulate and the cells undergo apoptosis. This is called synthetic lethality.

6. Symptoms

Ovarian cancer has been called the 'silent killer' because its early symptoms are extremely nonspecific. In reality, however, symptoms are present in about 70–75% of patients; the problem is that these symptoms are hard to distinguish from common gastrointestinal and urinary symptoms.

Main symptoms

Abdominal bloating, pelvic pain, anorexia and urinary frequency that occur 12 or more times per month and are new or worsening within 1 year are high-risk symptoms of ovarian cancer requiring immediate medical evaluation.

7. Signs

Physical examination findings

Signs of hormone hypersecretion (functioning ovarian tumors)

8. Screening

To date, ovarian cancer screening of the general population is not recommended. Large clinical trials (UKCTOCS, PLCO) confirmed that combined CA-125 + transvaginal ultrasound screening did not significantly reduce ovarian cancer mortality.

Surveillance of high-risk groups

Limitations of screening biomarkers

CA-125 is positive in only about 50–60% of early ovarian cancers (stage I) and is also elevated in benign conditions such as endometriosis, pelvic inflammatory disease, menstruation and pregnancy. HE4 (Human Epididymis Protein 4) has higher specificity than CA-125 and is used together with it to calculate the ROMA (Risk of Ovarian Malignancy Algorithm) index.

9. Diagnosis

Blood tests

Imaging

FIGO 2014 staging

StageDefinition
IAConfined to one ovary, capsule intact, no surface tumor, negative washings
IBConfined to both ovaries, capsule intact, no surface tumor, negative washings
ICIA/IB with any of capsule rupture, surface tumor, or positive washings/ascites
IIA/IIBPelvic extension (uterus, fallopian tubes, other pelvic structures)
IIIA~IIICPeritoneal metastasis (outside the pelvis); lymph node metastasis
IVA/IVBPleural effusion (cytology positive)/distant organ metastasis

Final histological diagnosis

Intraoperative frozen section examination confirms malignancy and determines the extent of surgery. Final pathology confirms histologic type (HGSOC, LGSOC, CCC, endometrioid, mucinous, other), grade, depth of invasion, lymph node status and peritoneal metastasis. Immunohistochemistry: WT1, p53 (overexpression/complete loss pattern), PAX8 and ER/PR are used in diagnosing HGSOC.

10. Treatment

Surgical treatment

The surgical principle for epithelial ovarian cancer is 'maximal tumor debulking (debulking surgery).' R0 (complete resection) or minimization of residual tumor (<1 cm) is the most important surgical goal determining prognosis.

Chemotherapy

PARP inhibitor maintenance therapy

Treatment of recurrent ovarian cancer

11. Prognosis

5-year survival rate by stage

FIGO stage5-year survival (US/worldwide)Korea
Stage I80~93%Diagnosis at stage I is rare, but prognosis is favorable
Stage II60~70%—
Stage III25~45%—
Stage IV10~20%44.4% (all distant metastasis)
Overall (Korea)~63.8%(2010~2014)Based on KCCR

Prognostic factors

12. Prevention

Oral contraceptives

Use of combined oral contraceptives (COC) is the most powerful chemopreventive measure, reducing the risk of ovarian cancer by 40–50%. The protective effect increases in proportion to the duration of use (50% reduction with 5 years of use) and persists for up to 15–20 years after stopping. The ovarian cancer preventive effect of COC has also been confirmed in BRCA1/2 mutation carriers, but it must be balanced against a possible slight increase in breast cancer risk.

Risk-reducing salpingo-oophorectomy (RRSO)

In BRCA1/2 mutation carriers, RRSO (risk-reducing salpingo-oophorectomy) is the most effective preventive method, reducing the risk of ovarian cancer by about 80–96%. Recommended timing: age 35–40 or after completion of childbearing for BRCA1 mutations, and age 40–45 for BRCA2 mutations. Performing only risk-reducing salpingectomy (RRLS) before RRSO is also being studied at some institutions. In Korea, prophylactic surgery for women with confirmed BRCA1/2 mutations is covered by National Health Insurance.

Childbirth and breastfeeding

Childbirth (multiparity) and breastfeeding lower the risk of ovarian cancer. A first delivery reduces risk by about 40–50%, with each additional delivery reducing it by a further 10–15%. Breastfeeding reduces risk in proportion to its duration.

Genetic counseling and genetic testing

In high-risk women with a family history (ovarian or breast cancer in first- or second-degree relatives), genetic counseling and panel testing for BRCA1/2 and other HRR genes are performed. In Korea, high-risk women can be tested through the state-supported genetic testing coverage system. When a mutation is confirmed, prophylactic surgery or an enhanced surveillance program is individualized.

Treatment of endometriosis

Given the confirmed association between endometriosis and clear cell and endometrioid ovarian cancer, active treatment and follow-up of endometriosis may have an indirect preventive effect.

13. References

  1. Sung H, et al. Global Cancer Statistics 2020. CA Cancer J Clin. 2021;71(3):209-249.
  2. TCGA Research Network. Integrated Genomic Analyses of Ovarian Carcinoma. Nature. 2011;474(7353):609-615.
  3. Clinical Outcomes of PARP Inhibitors as Maintenance Therapy in Korean Ovarian Cancer. PMC11593207. 2024.
  4. Real-world efficacy of olaparib in Korean ovarian cancer patients with exploratory BRCA analysis. PubMed 39923681. 2025.
  5. Comparison of olaparib and niraparib in BRCA-mutated, newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2024.
  6. Ray-Coquard I, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer (PAOLA-1). N Engl J Med. 2019;381(25):2416-2428.
  7. Mirvetuximab Soravtansine FDA Full Approval (ELAHERE). FDA. March 22, 2024. NCI Cancer Currents Blog.
  8. Moore KN, et al. Mirvetuximab Soravtansine in FRα-positive platinum-resistant ovarian cancer (MIRASOL). N Engl J Med. 2023;389(23):2162-2174.
  9. Cancer Statistics in Korea 2023. PMC13093029. 2026.
  10. Korean Society of Gynecologic Oncology. Clinical Practice Guidelines for Ovarian Cancer: 2025 Update. J Gynecol Oncol. 2025;36:e69.
  11. Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights. ESMO Open. 2024.
  12. Incidence and survival of gynecologic cancer in Korea 1999-2019: KCCR. PMC10663396. 2023.